More Stories

Obesity Care August 17, 2026

Just How Bad is BMI at Predicting CVD Risk? August 17, 2026

We all know BMI is pretty useless for predicting CV risk, and a new JACC analysis puts hard numbers on just how much it misses, including a high-risk group hiding in plain sight among "normal weight" patients.

Surgeries & Interventions August 13, 2026

More Interventional Cardiologists, More Low-Value Stents August 13, 2026

The old adage that "built capacity gets used" applies to cardiology too. A Lown Institute study found that regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.

Cardiology Business August 10, 2026

iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026

iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M.

Cardiology Pharmaceuticals August 6, 2026

ZEUS Tells Us Inflammation Might Not Be the Answer August 6, 2026

Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD.

Cardiology August 3, 2026

How to Make Cardiologists Love Academia Again August 3, 2026

Cardiology is one of the most data-driven medical specialties a physician can pursue. So why is the source of that data – cardiac academia – declining in both workforce and prestige?

Cardiology Pharmaceuticals July 31, 2026

Another Look at Attruby Reveals Bolstered Benefits July 31, 2026

As the ATTR-CM market gets more crowded, medications will have to prove their place, and a sub-analysis of the ATTRibute-CM trial shows BridgeBio’s Attruby (acoramidis) has the efficacy to remain competitive.

Get twice-weekly insights on the biggest stories shaping cardiology.